Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology.

TDP-43 TDP-43C9orf72 corticobasal degeneration (CBD) frontotemporal lobar degeneration (FTLD) limbic-predominant age-related encephalopathy neuropathological change (LATE-NC)

Journal

Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829

Informations de publication

Date de publication:
02 2022
Historique:
revised: 17 11 2021
received: 18 08 2021
accepted: 18 11 2021
pubmed: 26 11 2021
medline: 1 4 2022
entrez: 25 11 2021
Statut: ppublish

Résumé

Accumulating evidence suggests that patients with frontotemporal lobar degeneration (FTLD) can have pathologic accumulation of multiple proteins, including tau and TDP-43. This study aimed to determine the frequency and characteristics of concurrent tau pathology in FTLD with TDP-43 pathology (FTLD-TDP). The study included 146 autopsy-confirmed cases of FTLD-TDP and 55 cases of FTLD-TDP with motor neuron disease (FTLD-MND). Sections from the basal forebrain were screened for tau pathology with phosphorylated-tau immunohistochemistry. For cases with tau pathology on the screening section, additional brain sections were studied to establish a diagnosis. Genetic analysis of C9orf72, GRN and MAPT was performed on select cases. We found 72 cases (36%) with primary age-related tauopathy (PART), 85 (42%) with ageing-related tau astrogliopathy (ARTAG), 45 (22%) with argyrophilic grain disease (AGD) and 2 cases (1%) with corticobasal degeneration (CBD). Patients with ARTAG or AGD were significantly older than those without these comorbidities. One of the patients with FTLD-TDP and CBD had C9orf72 mutation and relatively mild tau pathology, consistent with incidental CBD. The coexistence of TDP-43 and tau pathologies was relatively common, particularly PART and ARTAG. Although rare, patients with FTLD can have multiple neurodegenerative proteinopathies. The absence of TDP-43-positive astrocytic plaques may suggest that CBD and FTLD-TDP were independent disease processes in the two patients with both tau and TDP-43 pathologies. It remains to be determined if mixed cases represent a unique disease process or two concurrent disease processes in an individual.

Identifiants

pubmed: 34823271
doi: 10.1111/nan.12778
pmc: PMC9300011
doi:

Substances chimiques

DNA-Binding Proteins 0
TARDBP protein, human 0
tau Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12778

Subventions

Organisme : NINDS NIH HHS
ID : U54 NS100693
Pays : United States

Informations de copyright

© 2021 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

Références

Acta Neuropathol. 2013 Feb;125(2):303-10
pubmed: 23053136
Neuropathol Appl Neurobiol. 2021 Feb;47(1):61-72
pubmed: 32365404
J Histochem Cytochem. 2007 Jul;55(7):687-700
pubmed: 17341475
Acta Neuropathol. 2015 Jan;129(1):53-64
pubmed: 25367383
Curr Opin Neurol. 2019 Apr;32(2):279-291
pubmed: 30672825
J Neuropathol Exp Neurol. 2003 Dec;62(12):1287-301
pubmed: 14692704
Acta Neuropathol. 2013 Oct;126(4):545-54
pubmed: 23922030
J Mol Neurosci. 2011 Nov;45(3):384-9
pubmed: 21720721
Neuropathol Appl Neurobiol. 2011 Jun;37(4):358-65
pubmed: 20942898
Acta Neuropathol. 2016 Jan;131(1):87-102
pubmed: 26659578
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Neuropathol Appl Neurobiol. 2021 Dec;47(7):931-941
pubmed: 33763863
Acta Neuropathol. 2016 Apr;131(4):571-85
pubmed: 26810071
Neuropathol Appl Neurobiol. 2014 Dec;40(7):844-54
pubmed: 24861427
J Neuropathol Exp Neurol. 2002 Jun;61(6):547-56
pubmed: 12071638
Acta Neuropathol. 2015 Apr;129(4):469-91
pubmed: 25549971
Biochem Biophys Res Commun. 2006 Dec 22;351(3):602-11
pubmed: 17084815
Nat Biomed Eng. 2020 Aug;4(8):787-800
pubmed: 32747831
Brain. 2019 Jun 1;142(6):1503-1527
pubmed: 31039256
Acta Neuropathol. 2011 Dec;122(6):673-90
pubmed: 22083254
Brain. 2019 Sep 1;142(9):e47
pubmed: 31359030
Brain. 2016 Dec;139(Pt 12):3237-3252
pubmed: 27797812
J Neuropathol Exp Neurol. 2008 Jun;67(6):555-64
pubmed: 18520774
Brain. 2021 Aug 17;144(7):2186-2198
pubmed: 33693619
Neuron. 2011 Oct 20;72(2):245-56
pubmed: 21944778
J Neuropathol Exp Neurol. 2020 Mar 1;79(3):296-304
pubmed: 31999351
Brain. 2012 Mar;135(Pt 3):693-708
pubmed: 22300873
Brain. 2018 Jul 1;141(7):2181-2193
pubmed: 29878075
Acta Neuropathol. 2013 Feb;125(2):289-302
pubmed: 23053135
Neuron. 2013 Feb 20;77(4):639-46
pubmed: 23415312
Acta Neuropathol. 2010 Jul;120(1):55-66
pubmed: 20512649
Neuropathol Appl Neurobiol. 2021 Dec;47(7):1050-1059
pubmed: 33969528
J Neuropathol Exp Neurol. 2004 Sep;63(9):911-8
pubmed: 15453090
J Neuropathol Exp Neurol. 2002 Nov;61(11):935-46
pubmed: 12430710
Acta Neuropathol. 2014 Dec;128(6):755-66
pubmed: 25348064
Nature. 2006 Aug 24;442(7105):916-9
pubmed: 16862116
Nat Rev Neurol. 2019 Oct;15(10):565-581
pubmed: 31501588
Acta Neuropathol. 2011 Jul;122(1):111-3
pubmed: 21644037
Neuropathol Appl Neurobiol. 2018 Dec;44(7):707-721
pubmed: 29660838
Commun Biol. 2021 Sep 21;4(1):1107
pubmed: 34548609
Neuropathol Appl Neurobiol. 2022 Feb;48(2):e12778
pubmed: 34823271
Acta Neuropathol. 2012 Jan;123(1):1-11
pubmed: 22101365
J Neurol. 2018 Dec;265(12):2960-2971
pubmed: 30324308
Acta Neuropathol. 2018 Sep;136(3):389-404
pubmed: 29926172
Science. 2006 Oct 6;314(5796):130-3
pubmed: 17023659
Mov Disord. 2017 Feb;32(2):246-255
pubmed: 28009087
Lancet Neurol. 2020 Feb;19(2):145-156
pubmed: 31810826
Neurology. 2002 Jun 25;58(12):1791-800
pubmed: 12084879

Auteurs

Shunsuke Koga (S)

Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.

Xiaolai Zhou (X)

Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China.

Aya Murakami (A)

Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.

Cristhoper Fernandez De Castro (C)

Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.

Matthew C Baker (MC)

Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.

Rosa Rademakers (R)

Applied and Translational Neurogenomics, VIB Center for Molecular Neurology, Antwerp, Belgium.
Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

Dennis W Dickson (DW)

Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH